ArticleAnalytical chemistry2025
Quantitative Assessment of a Novel Device Designed for Patient-centric Sampling of Dried Plasma Using Targeted Proteomics.
Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Technological advancements have significantly enhanced proteomics by improving the quality, depth, and timeliness of proteomic data, making mass spectrometry a promising tool for personalized medicine. To enable successful longitudinal population-level monitoring, it is essential to have cost-efficient and convenient sample collection methods that yield reliable results. Microsampling performed by patients in their own homes fulfills this requirement. In this study, we evaluate a novel microsampling device that readily prepares a dried plasma sample from blood collected through a finger prick. The device was assessed quantitatively through a targeted proteomics approach, using a selection of stable isotope-labeled protein fragments as standards for plasma proteins spanning a range from 1300 μM to 30 nM. All samples were analyzed using selected reaction monitoring to ensure quantitative robustness. The device was assessed both from a storage perspective and across a group of healthy donors to ensure reliable performance between individuals. The dried plasma obtained from the device shows an excellent quantitative correlation with conventional plasma (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.